Frontier Medicines Stock

Founded with a mission to address the unmet needs in drug discovery, Frontier Medicines is a pioneering biopharmaceutical company specializing in precision medicine. The company is dedicated to developing therapies that target disease-causing proteins traditionally considered undruggable. Frontier Medicines employs advanced technologies such as chemoproteomics, covalent chemistry, and machine learning, which are integrated into their proprietary Frontier™ and AutoTAC™ platforms. These platforms enable the identification and targeting of proteins that play a crucial role in the development and progression of diseases, particularly in oncology. A key area of focus for Frontier Medicines is the creation of precision medicines tailored to genetically-defined patient populations. This approach not only enhances the effectiveness of treatments but also minimizes potential side effects by targeting the root cause of the disease at a molecular level. The company's pipeline includes innovative candidates aimed at some of the most challenging targets in cancer research, such as the KRASG12C mutation. Frontier Medicines operates from its headquarters in South San Francisco, with an additional office in Boston, both of which are strategically located in major biotech hubs. The company collaborates with leading academic institutions, industry partners, and investors to accelerate the development and commercialization of its therapies, aiming to bring life-changing treatments to patients in need.